Harpreet Singh, PhDManaging Director, CSO and Co-Founder at Immatics Biotechnologies GmbH
Dr Harpreet Singh co-founded Immatics in 2000 and Immatics US in 2015.
Since 2015, Dr Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT) in close collaboration with MD Anderson Cancer Center.
Since 2000 he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapeutics with clinical utility. Dr Singh has played a leading role in raising over US$230m of venture capital funding over several financing rounds and US$20m from the State of Texas CPRIT fund.
Dr Singh is the inventor on numerous patents and patent applications and has co-authored approx. 30 publications in peer-reviewed journals including Nature Medicine, Nature Biotechnology, Lancet Oncology and Journal of Experimental Medicine, Brain and Blood. A scholar of Prof. Hans-Georg Rammensee, Dr Singh completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.